Since late 2020, Eli Lilly shares have climbed over 635% as revenues rose from $24.54 billion in 2020 to $45.04 billion in 2024 and net income nearly doubled from $6.19 billion to $10.59 billion over the same period. Investor sentiment drove the trailing P/E multiple from 13× in 2016 to a current multiple of 52×, underscoring expectations for continued blockbuster sales and pipeline success. While shares retreated 6% in recent days, they remain up 34.1% over the past six months, reflecting strong confidence in the company’s growth trajectory despite intensifying competition in the weight-loss segment and occasional volatility.

First, Lilly’s innovated pipeline centers on GLP-1 compounds such as tirzepatide (Mounjaro/Zepbound), with combined 2025 sales of $24.8 billion and consensus forecasts of $62 billion by 2030. Second, strategic acquisitions—16 since 2020, including a $1.2 billion deal for Ventyx Biosciences—bolster late-stage assets like MORF-057 in inflammatory bowel disease. Third, operational efficiency gains, driven by ongoing investments in manufacturing scale and cost controls, are expected to sustain net income growth rates above top-line expansion, supporting margins above 20% in the medium term.

Analyst consensus projects Eli Lilly revenue rising from $52.80 billion in 2025 to $96.67 billion by 2030, while net income climbs from $17.29 billion to $41.12 billion over the same period. Assumed P/E multiples decline gradually from 50× in 2026 to 38× by 2030, reflecting maturation of the portfolio. Under these assumptions, EPS grows from $19.11 in 2025 to $46.29 in 2030. Forecast models yield potential total returns of approximately 17.7% in 2026, accelerating to 65.4% by 2030 as revenue growth averages 13% annually and margin expansion continues.